A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus

CATEGORIES: Systemic Lupus Erythematosus

First posted April 1, 2022, Updated July 11, 2022; Recruiting

The purpose of this  Phase 3 study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.

To Learn More Contact

Call RemeGen at 301-284-1015 or by email to RC18_SLEstudy@remegenbio.com

ClinicalTrials.gov identifier (NCT number): NCT05306574

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up